TGF-β/activin can elicit opposing tumor promoting and suppressing effects in cancer [4], which is attributed, in part, to changes in SMAD-interacting (transcription) factors or rerouting through non-canonical signaling pathways [5,6,7,8]. The gene discussed is TGFB1; the disease is neoplasm.